Hyogo College Of Medicine;Mitsubishi Tanabe Pharma Corporation
发明人:
申请号：
EP18851250.3
公开号：
EP3677281A1
申请日:
2018.08.31
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
To provide a therapeutic agent for endometriosis and adenomyosis uteri. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis uteri, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found to be useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.
